Quick Answer
CITIUS ONCOLOGY, INC. reported Operating Income of -$23.52 million for fiscal year 2025.
CITIUS ONCOLOGY, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$23.52M | -14.3% |
| 2024 | -$20.57M | -1930.7% |
| 2023 | -$1.01M | -633.5% |
| 2022 | -$138.1K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$5.25M | +17.9% | -6.2% |
| June 30, 2025 | -$4.94M | -6.8% | +22.7% |
| December 31, 2024 | -$6.39M | — | -38.2% |
| June 30, 2024 | -$4.63M | -2219.6% | -1624.4% |
| March 31, 2024 | -$268.4K | -81.5% | +36.3% |
| September 30, 2023 | -$421.5K | — | -111.2% |
| June 30, 2023 | -$199.6K | — | -34.9% |
| March 31, 2023 | -$147.9K | — | — |
- CITIUS ONCOLOGY, INC. showed a decrease of -14.3% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, CITIUS ONCOLOGY, INC.’s operating income has declined by 16931.3% (from -$138.1 thousand to -$23.52 million).
- The most recent figure is from CITIUS ONCOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: